Helmholtz Zentrum München

HMGU

As German Research Center for Environmental Health, HelmholtzZentrum München (HMGU) seeks to further the development of prevention and therapy strategies for diabetes mellitus – with a special focus on personalized medicine. The Helmholtz Diabetes Center understands diabetes to be a complex, systemic disease in which both genetic and environmental factors – in particular lifestyle – interact. Here basic research and clinical research are intertwined in close interdisciplinary cooperation with the Munich universities.


Institutes and associated groups

  • Institute of Diabetes Research: Prof. Dr. Ziegler, Dr. Achenbach
  • Institute of Diabetes and Obesity: Prof. Dr. Tschöp, Dr. Pfluger
  • Institute of Diabetes and Cancer: Prof. Dr. Stephan Herzig
  • Institute of Diabetes and Regeneration Research: Prof. Dr. Lickert, Dr. Burtscher
  • Institute of Experimental Genetics: Prof. Hrabě de Angelis, PD Dr. Beckers, Dr. Teperino
  • Institute of Computational Biology: Prof. Fabian Theis, Dr. Jan Krumsiek (DZD-Core Unit Computational Biology)
  • Clinical Cooperation Group Nutrigenomics und Typ-2-Diabetes mellitus, TUM: Prof. Dr. Hans Hauner
  • Clinical Cooperation Group Prediction and Subclassification of Typ-2-Diabetes mellitus, LMU: Prof. Dr. Seissler
  • Institute of Epidemiology I: Dr. Joachim Heinrich (acting)
  • Institute of Epidemiology II: Prof. Dr. Peters
  • Research Unit  Molecular Epidemiology: Prof. Peters (acting), Dr. Grallert, Dr. Wang-Sattler
  • Institute of Genetic Epidemiology: Prof. Strauch
  • Institut of Health Economics and Health Care Management: Prof. Dr. Leidl, Prof. Dr. Holle
  • Genom Analysis Center: Prof. Dr. Adamski
  • Institute of Human Genetics: Prof. Dr. Meitinger, Dr. Strom
  • Research Unit Analytical BioGeoChemistry: Prof. Dr. Schmitt-Kopplin

 

Contribution to the DZD research program

  • Establishment and characterization of relevant mouse models
  • Development of a vaccine strategy for type 1 diabetics
  • Identification of early predictive metabolic markers, personalized type 2 diabetes risk prognosis
  • Differentiation of embryonic stem cells into insulin-secreting cells
  • Drug development
  • Computational Biology
  • Participation in the clinical studies of the DZD
  • KORA-Cohort

Speaker

Prof. Dr. Dr. h.c. Martin Hrabě de Angelis

Director of the Institute of Experimental Genetics
Helmholtz Zentrum München

Contact

Helmholtz Zentrum München – German Research Center for Environmental Health
Ingolstädter Landstrasse 1
85764 Neuherberg
Germany

+49 (0)89 3187 3302

hrabe(at)helmholtz-muenchen.de

"Diabetes Research at the HMGU" (in German language)

To find out more, listen to the podcast (German only) with Professor Hrabĕ de Angelis discussing important aspects of research conducted in the DZD.